Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 241,700 shares, an increase of 536.1% from the November 30th total of 38,000 shares. Based on an average trading volume of 313,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 16.6% of the shares of the company are short sold.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is owned by hedge funds and other institutional investors.

Aptevo Therapeutics Stock Performance

Aptevo Therapeutics stock opened at $4.81 on Friday. Aptevo Therapeutics has a 12 month low of $3.65 and a 12 month high of $399.60. The business has a 50 day simple moving average of $242.49 and a 200-day simple moving average of $402.06.

Wall Street Analyst Weigh In

APVO has been the topic of several recent research reports. Roth Mkm dropped their price objective on shares of Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating on the stock in a research note on Monday, September 23rd. StockNews.com assumed coverage on shares of Aptevo Therapeutics in a report on Monday, December 9th. They issued a “sell” rating for the company.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.